211 related articles for article (PubMed ID: 33986248)
1. A KLF4/PiHL/EZH2/HMGA2 regulatory axis and its function in promoting oxaliplatin-resistance of colorectal cancer.
Deng X; Kong F; Li S; Jiang H; Dong L; Xu X; Zhang X; Yuan H; Xu Y; Chu Y; Peng H; Guan M
Cell Death Dis; 2021 May; 12(5):485. PubMed ID: 33986248
[TBL] [Abstract][Full Text] [Related]
2. Long noncoding RNA PiHL regulates p53 protein stability through GRWD1/RPL11/MDM2 axis in colorectal cancer.
Deng X; Li S; Kong F; Ruan H; Xu X; Zhang X; Wu Z; Zhang L; Xu Y; Yuan H; Peng H; Yang D; Guan M
Theranostics; 2020; 10(1):265-280. PubMed ID: 31903119
[TBL] [Abstract][Full Text] [Related]
3. TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability.
Zhou S; Peng J; Xiao L; Zhou C; Fang Y; Ou Q; Qin J; Liu M; Pan Z; Hou Z
Cell Death Dis; 2021 May; 12(5):463. PubMed ID: 33966039
[TBL] [Abstract][Full Text] [Related]
4. Elevating H3K27me3 level sensitizes colorectal cancer to oxaliplatin.
Wang Q; Chen X; Jiang Y; Liu S; Liu H; Sun X; Zhang H; Liu Z; Tao Y; Li C; Hu Y; Liu D; Ye D; Liu Y; Wang M; Zhang X
J Mol Cell Biol; 2020 Feb; 12(2):125-137. PubMed ID: 31065671
[TBL] [Abstract][Full Text] [Related]
5. LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145.
Gao R; Fang C; Xu J; Tan H; Li P; Ma L
Arch Biochem Biophys; 2019 Mar; 663():183-191. PubMed ID: 30639170
[TBL] [Abstract][Full Text] [Related]
6. MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2.
Li P; Zhang X; Wang H; Wang L; Liu T; Du L; Yang Y; Wang C
Mol Cancer Ther; 2017 Apr; 16(4):739-751. PubMed ID: 28069878
[TBL] [Abstract][Full Text] [Related]
7. The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer.
Sun W; Li J; Zhou L; Han J; Liu R; Zhang H; Ning T; Gao Z; Liu B; Chen X; Ba Y
Theranostics; 2020; 10(5):1981-1996. PubMed ID: 32104496
[TBL] [Abstract][Full Text] [Related]
8. Suppression MGP inhibits tumor proliferation and reverses oxaliplatin resistance in colorectal cancer.
Huang C; Wang M; Wang J; Wu D; Gao Y; Huang K; Yao X
Biochem Pharmacol; 2021 Jul; 189():114390. PubMed ID: 33359068
[TBL] [Abstract][Full Text] [Related]
9. LncRNA-NEF suppressed oxaliplatin resistance and epithelial-mesenchymal transition in colorectal cancer through epigenetically inactivating MEK/ERK signaling.
Shi CJ; Xue ZH; Zeng WQ; Deng LQ; Pang FX; Zhang FW; Fu WM; Zhang JF
Cancer Gene Ther; 2023 Jun; 30(6):855-865. PubMed ID: 36782047
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer.
Li Y; Gan Y; Liu J; Li J; Zhou Z; Tian R; Sun R; Liu J; Xiao Q; Li Y; Lu P; Peng Y; Peng Y; Shu G; Yin G
Signal Transduct Target Ther; 2022 Mar; 7(1):87. PubMed ID: 35351858
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation.
Zhang Q; Wang C; Han X; Yang G; Ge Z; Zhang G
Biochem Biophys Res Commun; 2018 Sep; 503(4):2333-2339. PubMed ID: 29964008
[TBL] [Abstract][Full Text] [Related]
12. Lnc-RP11-536 K7.3/SOX2/HIF-1α signaling axis regulates oxaliplatin resistance in patient-derived colorectal cancer organoids.
Li Q; Sun H; Luo D; Gan L; Mo S; Dai W; Liang L; Yang Y; Xu M; Li J; Zheng P; Li X; Li Y; Wang Z
J Exp Clin Cancer Res; 2021 Nov; 40(1):348. PubMed ID: 34740372
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis.
Wang H; Li H; Zhang L; Yang D
Biomed Pharmacother; 2018 Oct; 106():1607-1615. PubMed ID: 30119236
[TBL] [Abstract][Full Text] [Related]
14. PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.
Yang L; Ma DW; Cao YP; Li DZ; Zhou X; Feng JF; Bao J
Theranostics; 2021; 11(8):3742-3759. PubMed ID: 33664859
[No Abstract] [Full Text] [Related]
15. MEG3 is a prognostic factor for CRC and promotes chemosensitivity by enhancing oxaliplatin-induced cell apoptosis.
Li L; Shang J; Zhang Y; Liu S; Peng Y; Zhou Z; Pan H; Wang X; Chen L; Zhao Q
Oncol Rep; 2017 Sep; 38(3):1383-1392. PubMed ID: 28731151
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of AC092894.1 promotes oxaliplatin resistance in colorectal cancer via the USP3/AR/RASGRP3 axis.
Zheng Z; Wu M; Li H; Xu W; Yang M; Pan K; Ni Y; Jiang T; Zheng H; Jin X; Zhang Y; Ding L; Fu J
BMC Med; 2023 Apr; 21(1):132. PubMed ID: 37013584
[TBL] [Abstract][Full Text] [Related]
17. Long noncoding RNA SNHG14 facilitates colorectal cancer metastasis through targeting EZH2-regulated EPHA7.
Di W; Weinan X; Xin L; Zhiwei Y; Xinyue G; Jinxue T; Mingqi L
Cell Death Dis; 2019 Jul; 10(7):514. PubMed ID: 31273190
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNAs: Key regulators in oxaliplatin resistance of colorectal cancer.
Qi FF; Yang Y; Zhang H; Chen H
Biomed Pharmacother; 2020 Aug; 128():110329. PubMed ID: 32502843
[TBL] [Abstract][Full Text] [Related]
19. Long non-coding RNA PCAT6 targets miR-204 to modulate the chemoresistance of colorectal cancer cells to 5-fluorouracil-based treatment through HMGA2 signaling.
Wu H; Zou Q; He H; Liang Y; Lei M; Zhou Q; Fan D; Shen L
Cancer Med; 2019 May; 8(5):2484-2495. PubMed ID: 30938104
[TBL] [Abstract][Full Text] [Related]
20. Bioactive Peptides Sensitize Cells to Anticancer Effects of Oxaliplatin in Human Colorectal Cancer Xenografts in Nude Mice.
Li X; Xia L; Ouyang X; Suyila Q; Su L; Su X
Protein Pept Lett; 2019; 26(7):512-522. PubMed ID: 30950338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
